PathWhiz

PathWhiz ID	Pathway	Meta Data
PW144516 View Pathway	drug action Sulpiride Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 13:48 Last Updated: October 07, 2023 at 13:48
PW128078 View Pathway	drug action Sulpiride Mechanism of Action Action Pathway Homo sapiens Sulpiride is a substituted benzamide derivative and a selective dopamine D2 antagonist indicated to treat acute and chronic schizophrenia. Sulpiride is a selective dopamine D2 and D3 receptor antagonist. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Omolola Created On: July 13, 2023 at 13:02 Last Updated: July 13, 2023 at 13:02
PW146496 View Pathway	drug action Sultamicillin Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 18:20 Last Updated: October 07, 2023 at 18:20
PW145830 View Pathway	drug action Sulthiame Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 16:46 Last Updated: October 07, 2023 at 16:46
PW146633 View Pathway	drug action Sultopride Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 18:40 Last Updated: October 07, 2023 at 18:40
PW176407 View Pathway	metabolic Sultopride Predicted Metabolism Pathway Homo sapiens Metabolites of Sultopride are predicted with biotransformer. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Omolola Created On: December 07, 2023 at 16:55 Last Updated: December 07, 2023 at 16:55
PW144781 View Pathway	drug action Sumatriptan Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 14:25 Last Updated: October 07, 2023 at 14:25
PW128601 View Pathway	drug action Sumatriptan Mechanism of Action Action Pathway Homo sapiens Triptans are a class of medications used in the treatment of migraine headaches. Triptans act as antimigraine agents by selectively binding to the serotonin receptors 5-HT1B and 5-HT1D. Triptan binding to the vascular 5-HT1B receptors leads to vasoconstriction of the cranial arteries, which painfully dilate during a migraine attack. Sumatriptan is a 5-HT1B/1D receptor agonist and leads to vasoconstriction in the basilar artery and the blood vessels of the dura mater. It decreases peripheral nociception either by selective cranial vasoconstriction or an effect on trigeminovascular nerves. The blocking effect of sumatriptan indicated a peripheral effect on trigeminal vascular nerves in neurogenically mediated plasma extravasation. Sumatriptan inhibits the presynaptic terminal of the trigeminal nucleus caudalis, which leads to the reversal of facial allodynia. Triptans decrease transmission of the pain impulses to the trigeminal nucleus caudalis and reduce inflammatory mediators from trigeminal nerves, therefore reducing calcitonin gene-related peptide-mediated vasodilation. Migraine pain is associated with middle cerebral artery dilatation, which leads to a lower velocity of regional cerebral blood flow. Sumatriptan reverses the dilatation of MCA, which suggests that the 5-HT receptor system has a role in the pathogenesis of a migraine. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Omolola Created On: September 06, 2023 at 09:58 Last Updated: September 06, 2023 at 09:58
PW128477 View Pathway	drug action Sunitinib Action Pathway Homo sapiens Sunitinib is a chemotherapeutic agent and receptor tyrosine kinase inhibitor utilized in the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Approved by the US FDA on January 26, 2006, it's administered orally and operates as a multi-targeted small-molecule receptor tyrosine kinase (RTK) inhibitor. Its actions encompass inhibiting key signaling pathways by targeting various RTKs, including platelet-derived growth factor receptors (PDGF-R), vascular endothelial growth factor receptors (VEGF-R), and KIT (CD117) in GIST cases. Sunitinib also affects RET, CSF-1R, and flt3 RTKs. Indicated conditions for sunitinib include advanced RCC, adjuvant treatment post-nephrectomy for high-risk recurrent RCC, and well-differentiated pancreatic neuroendocrine tumors (pNET) with unresectable locally advanced or metastatic disease. Its mechanism entails inhibiting RTKs implicated in cancer progression, tumor growth, and angiogenesis. This inhibition encompasses PDGFRa, PDGFRb, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, and RET receptors. The primary metabolite mirrors sunitinib's potency in relevant assays. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Dorsa Yahya Rayat Created On: August 30, 2023 at 13:53 Last Updated: August 30, 2023 at 13:53
PW145351 View Pathway	drug action Sunitinib Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 15:38 Last Updated: October 07, 2023 at 15:38